Abstract: The invention relates to a pharmaceutical composition in the form of an oral film comprising levothyroxine and a film forming polymer. The oral film can be of various types such as and including a mouth dissolving or soluble film, non-mucoadhesive film, fast disintegrating film, buccal film, mucoadhesive film, sublingual film, edible film or wafer. The invention also relates to a process of preparation of such oral film compositions.

Abstract: The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to fusion molecule constructs wherein a tumor associated antigen (TAA) antibody (Ab) serves as a targeting moiety to selectively deliver a cytokine to a tumor cell for purposes of killing or inhibiting the growth or proliferation of said tumor cell. In various embodiments, the engineered fusion molecules comprise a TAA Ab fused to an interferon-alpha (IFN-?) mutant molecule. The engineered Ab-IFN-? mutant fusion molecules of the present invention demonstrate improved therapeutic index and preserved or increased efficacy as compared to Ab-wildtype IFN-? fusion molecules, and/or demonstrate improved PK properties as compared to Ab-wildtype IFN-? fusion molecules.

Abstract: A control device that may be implemented in a single IC chip is provided that is capable of controlling EAM bias voltages and DFB bias currents and of monitoring the EAM photocurrents and received signal strength indicators (RSSIs) in a multi-channel optical transceiver module. The control device IC chip can be manufactured at relatively low cost with relatively high yield, and can be implemented in a relatively small area. To implement the control device in a single IC chip, multiple supply voltage domains are used in the IC chip, one of which is a negative supply voltage domain and one of which is a positive supply voltage domain. In order to provide these different supply voltage domains, a level shift circuit is employed in the IC chip that converts signals from the positive to the negative supply voltage domain, and vice versa, and changes the voltage levels, as needed.

Abstract: A control device that may be implemented in a single IC chip is provided that is capable of controlling EAM bias voltages and DFB bias currents and of monitoring the EAM photocurrents and received signal strength indicators (RSSIs) in a multi-channel optical transceiver module. The control device IC chip can be manufactured at relatively low cost with relatively high yield, and can be implemented in a relatively small area. To implement the control device in a single IC chip, multiple supply voltage domains are used in the IC chip, one of which is a negative supply voltage domain and one of which is a positive supply voltage domain. In order to provide these different supply voltage domains, a level shift circuit is employed in the IC chip that converts signals from the positive to the negative supply voltage domain, and vice versa, and changes the voltage levels, as needed.

Abstract: The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to fusion molecule constructs wherein a tumor associated antigen (TAA) antibody (Ab) serves as a targeting moiety to selectively deliver a cytokine to a tumor cell for purposes of killing or inhibiting the growth or proliferation of said tumor cell. In various embodiments, the engineered fusion molecules comprise a TAA Ab fused to an interferon-alpha (IFN-?) mutant molecule. The engineered Ab-IFN-? mutant fusion molecules of the present invention demonstrate improved therapeutic index and preserved or increased efficacy as compared to Ab-wildtype IFN-? fusion molecules, and/or demonstrate improved PK properties as compared to Ab-wildtype IFN-? fusion molecules.

Abstract: The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to fusion molecule constructs wherein a tumor associated antigen (TAA) antibody (Ab) serves as a targeting moiety to selectively deliver a cytokine to a tumor cell for purposes of killing or inhibiting the growth or proliferation of said tumor cell. In various embodiments, the engineered fusion molecules comprise a TAA Ab fused to an interferon-alpha (IFN-?) mutant molecule. The engineered Ab-IFN-? mutant fusion molecules of the present invention demonstrate improved therapeutic index and preserved or increased efficacy as compared to Ab-wildtype IFN-? fusion molecules, and/or demonstrate improved PK properties as compared to Ab-wildtype IFN-? fusion molecules.

Abstract: The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to engineered fusion molecules comprising an antibody (Ab) which can target tumor cells (e.g., RITUXIN®), fused to one or more biologic moieties capable of inducing apoptosis in tumor cells, e.g., tumor necrosis factor super family (TNFSF) member ligands such as TNF-?, CD40L, CD95L (also “FasL/Apo-1L”) and TRAIL/Apo-2L. Importantly, the engineered fusion molecules of the present invention retain the death-inducing properties of the biologic moiety at optimum concentrations and with reduced systemic toxicities.

Abstract: The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to fusion molecule constructs wherein a tumor associated antigen (TAA) antibody (Ab) serves as a targeting moiety to selectively deliver a cytokine to a tumor cell for purposes of killing or inhibiting the growth or proliferation of said tumor cell. In various embodiments, the engineered fusion molecules comprise a TAA Ab fused to an interferon-alpha (IFN-?) mutant molecule. The engineered Ab-IFN-? mutant fusion molecules of the present invention demonstrate improved therapeutic index and preserved or increased efficacy as compared to Ab-wildtype IFN-? fusion molecules, and/or demonstrate improved PK properties as compared to Ab-wildtype IFN-? fusion molecules.

Abstract: The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to fusion molecule constructs wherein a tumor associated antigen (TAA) antibody (Ab) serves as a targeting moiety to selectively deliver a cytokine to a tumor cell for purposes of killing or inhibiting the growth or proliferation of said tumor cell. In various embodiments, the engineered fusion molecules comprise a TAA Ab fused to an interferon-alpha (IFN-?) mutant molecule. The engineered Ab-IFN-? mutant fusion molecules of the present invention demonstrate improved therapeutic index and preserved or increased efficacy as compared to Ab-wildtype IFN-? fusion molecules, and/or demonstrate improved PK properties as compared to Ab-wildtype IFN-? fusion molecules.

Abstract: The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to engineered fusion molecules comprising an antibody (Ab) which can target tumor cells (e.g., RITUXIN®), fused to one or more biologic moieties capable of inducing apoptosis in tumor cells, e.g., tumor necrosis factor super family (TNFSF) member ligands such as TNF-?, CD40L, CD95L (also “FasL/Apo-1L”) and TRAIL/Apo-2L. Importantly, the engineered fusion molecules of the present invention retain the death-inducing properties of the biologic moiety at optimum concentrations and with reduced systemic toxicities, thus improving the therapeutic index of the engineered fusion molecules.

Abstract: The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to fusion molecule constructs wherein a tumor associated antigen (TAA) antibody (Ab) serves as a targeting moiety to selectively deliver a cytokine to a tumor cell for purposes of killing or inhibiting the growth or proliferation of said tumor cell. In various embodiments, the engineered fusion molecules comprise a TAA Ab fused to an interferon-alpha (IFN-?) mutant molecule. The engineered Ab-IFN-? mutant fusion molecules of the present invention demonstrate improved therapeutic index and preserved or increased efficacy as compared to Ab-wildtype IFN-? fusion molecules, and/or demonstrate improved PK properties as compared to Ab-wildtype IFN-? fusion molecules.

Abstract: One embodiment of the invention is a portion of a test system that includes a timing generation circuit and a formatter that are coupled together, which are on a single CMOS (complementary metal oxide semiconductor) integrated circuit. The timing Generation circuit generates software words. The formatter receives the software words and provides a specified number of transitions per second and a specified edge placement resolution and accuracy. It is noted that the formatter includes a drive circuit and a response circuit. Specifically, the drive circuit includes a plurality of slices, where each slice receives an independent data stream and produces an independent formatted level. The response circuit includes a plurality of slices, where each slice receives an independent data stream and produces an independent strobe marker.

Abstract: The present invention relates to test systems for testing integrated circuit devices and to calibration associated systems and methods. One embodiment of the invention provides a test system formatter including: a plurality of event logic interfaces, each event logic interface capable of receiving and decoding timing signals; a plurality of delay line elements (DLEs), each DLE being coupled to a corresponding event logic interface and being capable of generating timing markers corresponding to signals received from the corresponding event logic interface; drive logic coupled to the plurality of DLEs, having first and second outputs and operative to produce first and second formatted levels on the first and second outputs in response to timing markers received from the plurality of DLEs; response logic coupled to the plurality of DLEs, having first and second inputs and operative to produce strobe markers in response to timing markers received from the plurality of DLEs; and a loop-back circuit.

Abstract: The present invention relates to test systems for testing integrated circuit devices and to calibration associated systems and methods. One embodiment of the invention provides an auto-calibration system. The system includes: a plurality of delay line elements (DLEs) adapted to be connected in a loop; a state machine coupled to the plurality of DLEs and operative to provide state data for the plurality of DLEs; a start oscillation signal receiving circuit coupled to the loop and operative to trigger the loop in response to receipt of a start oscillation signal; and a calibration circuit coupled to the loop and operative to acquire calibration data for the plurality of DLEs.

Abstract: The present invention relates to test systems for testing integrated circuit devices and to calibration associated systems and methods. One embodiment of the invention provides a method for providing formatted levels for use in a test system. The method includes: providing on a single CMOS IC, a timing generation circuit operative to provide timing information signals; and a formatter in communication with the timing generation circuit.

Abstract: This invention provides a computer based method for preparing a stem cell factor (SCF) analog comprising the steps of: (a) providing computer expression of the three dimensional structure of an SCF molecule using its crystal structure; (b) selecting from the computer expression of step (a) at least one site on the SCF molecule for alteration; (c) preparing a SCF molecule having an alteration at said at least one selected site; and (d) optionally, testing the SCF molecule for a desired characteristic. This invention also provides SCF analogs and SCF ligand analogs prepared according to the above-described method. Compositions comprising SCF analogs or SCF ligand analogs prepared according to the above-described method effective to treat a subject and a pharmaceutically acceptable carrier are provided, as are methods of treating a subject comprising administration of pharmaceutical compositions comprising the prepared SCF analogs and SCF ligand analogs prepared by the described methods.